A practical reference on lyophilization: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Analysis of the debris at the test site of the United States' first thermonuclear weapon, Ivy Mike (1 November 1952, Enewetak Atoll), besides einsteinium, fermium, plutonium and americium also revealed isotopes of berkelium, californium and curium, in particular 245Cm, 246Cm and smaller quantities of 247Cm, 248Cm and 249Cm. Atmospheric curium compounds are poorly soluble in common solvents and mostly adhere to soil particles. Soil analysis revealed about 4,000 times higher concentration of curium at the sandy soil particles than in water present in the soil pores. An even higher ratio of about 18,000 was measured in loam soils. The transuranic elements up to fermium, including curium, should have been present in the natural nuclear fission reactor at Oklo, but any quantities produced then would have long since decayed away.
==== Sen-chan ==== Senichi Enari (江成 仙一, Enari Sen'ichi), also known as "Sen-chan" (センちゃん), is the eccentric, yet calmest and smartest member, of the team, due in part to his ability to think things through and being able to do his best thinking while in a handstand, which he considers his "thinking pose". Sen-chan serves as Deka Green (デカグリーン, Deka Gurīn). The oldest of seven siblings from a poor family, he displays nycto- and claustrophobia after accidentally falling into a well when he was a child. He was subsequently rescued by a policeman, which inspired him to take up police work. Despite his usually calm demeanor, he is said to be scary when angered. He also displays a crush on his teammate Umeko, but avoids showing it publicly. As of the crossover film Mahō Sentai Magiranger vs. Dekaranger, they have moved in together. As Deka Green, Sen-chan wields the D-Knuckle and D-Rod, which can combine to form the D-Blaster (ディーブラスター, Dī Burasutā) rifle. He also shares riding the Machine Bull (マシンブル, Mashin Buru) police car with Umeko. Using the D-Rod, Sen-chan can perform the Green Crash (グリーンクラッシュ, Gurīn Kurasshu) attack. Sen-chan is portrayed by Yousuke Itou (伊藤 陽佑, Itō Yōsuke). As a child, he is portrayed by Kengo Tajima (田島 健吾, Tajima Kengo).
== Works cited == Bose, Romen (2010). The End of the War: Singapore's Liberation and the Aftermath of the Second World War. Singapore: Marshall Cavendish. ISBN 978-981-261-066-9. Legg, Frank (1965). The Gordon Bennett Story: From Gallipoli to Singapore. Sydney, New South Wales: Angus & Robertson. OCLC 3193299. Miksic, John N. (2013). Singapore & the Silk Road of the Sea, 1300–1800. Singapore: NUS Press. ISBN 978-9971-69-558-3. Smith, Colin (2006). Singapore Burning: Heroism and Surrender in World War II. Penguin military history. London: Penguin Books. ISBN 978-0-14-101036-6. Toland, John (1970). The Rising Sun: The Decline and Fall of the Japanese Empire, 1936–1945. New York, NY: Random House. LCCN 77-117669. OL 25646706M. Wigmore, Lionel (1957). The Japanese Thrust. Canberra: Australian War Memorial.
No visible clubbing – Fluctuation (increased ballotability) and softening of the nail bed only. No visible changes in nails. Mild clubbing – Loss of the normal <165° angle (Lovibond angle) between the nailbed and the fold (cuticula). Schamroth's window (see image) is obliterated. Clubbing is not obvious at a glance. Moderate clubbing – Increased convexity of the nail fold. Clubbing is apparent at a glance. Gross clubbing – Thickening of the whole distal (end part of the) finger (resembling a drumstick) Hypertrophic osteoarthropathy – Shiny aspect and striation of the nail and skin Schamroth's sign or Schamroth's window test (originally demonstrated by South African cardiologist Leo Schamroth on himself) is a popular test for clubbing. When the distal phalanges (bones nearest the fingertips) of corresponding fingers of opposite hands are directly opposed (place fingernails of the same finger on opposite hands against each other, nail to nail), a small diamond-shaped "window" is normally apparent between the nailbeds. If this window is obliterated, the test is positive, and clubbing is present.
For Ajax, Edgar Davids the first penalty taker's shot was saved by Peruzzi. The next two players scored, those being Litmanen and Arnold Scholten. Their final penalty taken by Sonny Silooy was also saved. Jugović's goal was the decisive penalty that gave Juventus its second title in the competition; Juventus won by a score of 4–2.
Sources: en.wikipedia.org
==== Nations ==== Bahrain: Bahrain called for a lasting solution that will prevent Iran from getting nuclear weapons or from doing things that could destabilize the region. France: President Emmanuel Macron said that he remained concerned about the "critical" situation in Lebanon, after Israel continued its strikes and occupation of southern Lebanon after the ceasefire, stating that this "cannot be a long-term solution." France also looked forward to securing shipping through the Strait of Hormuz. Germany: Germany urged Iran to respect the ceasefire and to allow ships to cross the Strait of Hormuz safely and freely. They also urged Iran to take advantage of the opportunity for negotiations. India: The Indian Ministry for External Affairs welcomed the US-Iran ceasefire agreement and called for an early end to the conflict for "unimpeded" trade flow through the Strait of Hormuz. Iraq: The Iraqi oil ministry said on 9 April that no Iraqi ships had crossed the Strait since the ceasefire came into effect. Kuwait: Kuwait's foreign ministry urged Iran and its "proxies, including factions, militias, and armed groups loyal to it" to cease all hostilities against Gulf Arab states. Qatar: Qatar's foreign ministry considered the ceasefire "an initial step toward de-escalation" and hoped Iran would "cease all hostile acts and practices that undermine regional stability." Russia: Russia welcomed the ceasefire and expressed hope that the United States would be able to resume peace negotiations in the Russo-Ukrainian war.
On 21 March, Japanese ambassador to Brazil Teiji Hayashi confirmed that prime minister Fumio Kishida would invite president Lula to the 49th G7 summit to be held from 19 to 21 May 2023 in Hiroshima, which formally took place on 6 April. In May 2023, Kishida met with Lula and announced that Japan was starting procedures to grant Brazilians travel visa exemptions and was opening a ¥30 billion line of credit to support health companies and other businesses in Brazil through Japan International Cooperation Agency (JICA). Lula said Brazil and Japan need to further develop their commercial, cultural, political and scientific relationship adding that "we have cultural bonds with Japan and a great Japanese-Brazilian community". Both leaders also discussed education, climate change, development and peace.
==== Non-peptide ==== CA7 – among smallest-known oxytocin receptor agonists; considerable selectivity over the vasopressin V1A receptor KNX-200 (KNX200) – series; chemical structure(s) not yet disclosed LIT-001 — improved social deficits in mice; non-selective over vasopressin receptors LIT-002 – extremely potent; improved social deficits in mice; non-selective over vasopressin receptors TC OT 39 – non-selective over vasopressin receptors WAY-267,464 – anxiolytic in mice; possibly non-selective over vasopressin receptors WJ0679 – among smallest-known oxytocin receptor agonists; produces prosocial effects in rodents
== Research == Muscimol has been clinically studied for a number of potential medical uses. It was assessed in small clinical studies in the treatment of Huntington's disease, tardive dyskinesia, and schizophrenia in the 1970s but was not found to be useful for these indications. Another study evaluated muscimol in schizophrenics with tardive dyskinesia in 1992. Studies also assessed the biochemical effects of muscimol in humans in the late 1970s and early 1980s. According to Povl Krogsgaard-Larsen, muscimol was too toxic and non-selective and as such was not developed for use as a pharmaceutical drug. Instead, the synthetic analogue gaboxadol (THIP), which was more selective and much less toxic, was developed. In 2019, a phase 1 clinical trial of muscimol for drug-resistant epilepsy was published. It has also been formally investigated for potential treatment of Alzheimer's disease and Parkinson's disease. A 2023 systematic review and meta-analysis of 22 preclinical studies found that muscimol reduces neuropathic pain in animals, with effects beginning within 15 minutes and lasting up to 3 hours. Muscimol has never been approved as a pharmaceutical drug for any use anywhere in the world.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.